{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:40:53Z","timestamp":1795041653323,"version":"4.10.2"},"reference-count":198,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Over the past few years, cellular immunotherapy has emerged as a promising treatment for certain hematologic cancers, with various CAR-T therapies now widely used in clinical settings. However, challenges related to the production of autologous cell products and the management of CAR-T cell toxicity highlight the need for new cell therapy options that are universal, safe, and effective. Natural killer (NK) cells, which are part of the innate immune system, offer unique advantages, including the potential for off-the-shelf therapy. A recent first-in-human trial of CD19-CAR-NK infusion in patients with relapsed\/refractory lymphoid malignancies demonstrated safety and promising clinical activity. Building on these positive clinical outcomes, current research focuses on enhancing CAR-NK cell potency by increasing their\n                    <jats:italic>in vivo<\/jats:italic>\n                    persistence and addressing functional exhaustion. There is also growing interest in applying the successes seen in hematologic malignancies to solid tumors. This review discusses current trends and emerging concepts in the engineering of next-generation CAR- NK therapies. It will cover the process of constructing CAR-NK cells, potential targets for their manufacturing, and their role in various solid tumors. Additionally, it will examine the mechanisms of action and the research status of CAR-NK therapies in the treatment of solid tumors, along with their advantages, limitations, and future challenges. The insights provided may guide future investigations aimed at optimizing CAR-NK therapy for a broader range of malignancies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1574742","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T01:24:18Z","timestamp":1743989058000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":101,"title":["CAR-NK cell therapy: promise and challenges in solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Sahar","family":"Balkhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Zuccolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Di Spirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mortara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","unstructured":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00001-5","article-title":"National Institute for Health Research Global Health Research Unit on Global S: Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries","volume":"397","author":"GlobalSurg","year":"2021","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13244-021-01017-2","article-title":"Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe","volume":"12","author":"Albano","year":"2021","journal-title":"Insights Imaging."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063012","article-title":"Genetic therapy and molecular targeted therapy in oncology: Safety, pharmacovigilance, and perspectives for research and clinical practice","volume":"23","author":"Orzetti","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107603","article-title":"Genetically modified immune cells targeting tumor antigens","volume":"214","author":"Poorebrahim","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19\u201322 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121974","article-title":"CAR T cell locomotion in solid tumor microenvironment","volume":"11","author":"Nguyen","year":"2022","journal-title":"Cells."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084170","article-title":"CAR T cells in solid tumors: overcoming obstacles","volume":"25","author":"Rojas-Quintero","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082323","article-title":"The function of NK cells in tumor metastasis and NK cell-based immunotherapy","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR- transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumor adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01295","article-title":"Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2- specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":". J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"NK cell biology: An update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02045","article-title":"NK cell precursors in human bone marrow in health and inflammation","volume":"10","author":"Bozzano","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9060662","article-title":"Telomerase reverse transcriptase increases proliferation and lifespan of human NK cells without immortalization","volume":"9","author":"Streltsova","year":"2021","journal-title":"Biomedicines."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02078","article-title":"Human NK cell development: One road or many","volume":"10","author":"Cichocki","year":"2019","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: An important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1376595","article-title":"The memories of NK cells: Innate-adaptive immune intrinsic crosstalk","volume":"2016","author":"Gabrielli","year":"2016","journal-title":"J Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.013","article-title":"Natural killer cell memory","volume":"43","author":"O\u2019Sullivan","year":"2015","journal-title":"Immunity."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e008717","DOI":"10.1136\/jitc-2023-008717","article-title":"Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy","volume":"12","author":"Arellano-Ballestero","year":"2024","journal-title":"J Immunother Cancer."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2376410","article-title":"Natural killer cell memory: Challenges and opportunities for cancer immunotherapy","volume":"25","author":"Qu","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119521","article-title":"NK cells in cancer: Mechanisms of dysfunction and therapeutic potential","volume":"24","author":"Portale","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092339","article-title":"Regulation of NKG2D stress ligands and its relevance in cancer progression","volume":"14","author":"Jones","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103726","article-title":"Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer","volume":"21","author":"Sordo-Bahamonde","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910595","article-title":"Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies","volume":"13","author":"Seliger","year":"2022","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840844","article-title":"NK cells equipped with a chimeric antigen receptor that overcomes inhibition by HLA class I for adoptive transfer of CAR-NK cells","volume":"13","author":"Zhuang","year":"2022","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000327014","article-title":"Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance","volume":"3","author":"Groth","year":"2011","journal-title":"J Innate Immun"},{"key":"B42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","article-title":"NK cells are never alone: Crosstalk and communication in tumour microenvironments","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: Current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discovery"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/biom14081035","article-title":"CAR-NK cell therapy: A transformative approach to overcoming oncological challenges","volume":"14","author":"Li","year":"2024","journal-title":"Biomolecules."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12794","article-title":"Immunobiology of chimeric antigen receptor T cells and novel designs","volume":"290","author":"Walsh","year":"2019","journal-title":"Immunol Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.26","article-title":"NK cell education via nonclassical MHC and non-MHC ligands","volume":"14","author":"He","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708073","article-title":"PSMA-specific CAR-engineered T cells for prostate cancer: CD28 outperforms combined CD28-4-1BB \u201cSuper-stimulation","author":"Zuccolotto","year":"2021","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: Functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci Adv"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.01.008","article-title":"Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","volume":"20","author":"Allan","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12920-019-0489-4","article-title":"Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines","volume":"12","author":"Kulemzin","year":"2019","journal-title":"BMC Med Genomics"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020375","article-title":"Design and characterization of an \u201cAll-in-One\u201d lentiviral vector system combining constitutive anti-GD2 CAR expression and inducible cytokines","volume":"12","author":"Zimmermann","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2018.06.003","article-title":"A comprehensive review of signal peptides: structure, roles, and applications","volume":"97","author":"Owji","year":"2018","journal-title":"Eur J Cell Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2013.02.021","article-title":"Co-translational targeting and translocation of proteins to the endoplasmic reticulum","volume":"1833","author":"Nyathi","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2013.03.033","article-title":"Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases","volume":"1828","author":"Voss","year":"2013","journal-title":"Biochim Biophys Acta BBA Biomembranes."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.12.006","article-title":"Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials","volume":"31","author":"Cornetta","year":"2023","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113455","article-title":"Development of Inducible CD19-CAR T cells with a Tet-on system for controlled activity and enhanced clinical safety","volume":"19","author":"Gu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197349","article-title":"Feasibility of controlling CD38 CAR T cell activity with a Tet-on inducible CAR design","volume":"13","author":"Drent","year":"2018","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12896-019-0537-3","article-title":"Modulation of chimeric antigen receptor surface expression by a small molecule switch","volume":"19","author":"Juillerat","year":"2019","journal-title":"BMC Biotechnol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051302","article-title":"Adaptor CAR platforms-next generation of T cell-based cancer immunotherapy","volume":"12","author":"Arndt","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PloS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07667.x","article-title":"Replicative potential of human natural killer cells","volume":"145","author":"Fujisaki","year":"2009","journal-title":"Br J Haematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.700767","article-title":"Large scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy."},{"key":"B78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0022-1759(93)90102-d","article-title":"Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity","volume":"165","author":"Voshol","year":"1993","journal-title":"J Immunol Methods"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(86)90084-0","article-title":"Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity","volume":"90","author":"Fujiwara","year":"1986","journal-title":"J Immunol Methods"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell- mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PloS One"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.5095","article-title":"Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity","volume":"175","author":"Woll","year":"2005","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00055-3","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02873","article-title":"Expression of a recombinant high affinity IgG Fc receptor by engineered NK cells as a docking platform for therapeutic mAbs to target cancer cells","volume":"9","author":"Snyder","year":"2018","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/cancers1303057","article-title":"Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy","volume":"13","author":"Fern\u00e1ndez","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050451","article-title":"Building a better defense: expanding and improving natural killer cells for adoptive cell therapy","volume":"13","author":"Maia","year":"2024","journal-title":"Cells."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1615\/critrevoncog.2014010931","article-title":"Clinical grade purification and expansion of natural killer cells","volume":"19","author":"Lapteva","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"B89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/imr.12793","article-title":"Cellular therapy: adoptive immunotherapy with expanded natural killer cells","volume":"290","author":"Lee","year":"2019","journal-title":"Immunol Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2017.098","article-title":"Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice","volume":"29","author":"G\u00e1ndara","year":"2018","journal-title":"Hum Gene Ther Methods"},{"key":"B92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J Mol Med (Berl)."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"M\u00fcller","year":"2020","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","article-title":"Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.202101081","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.05.022","article-title":"Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors","volume":"32","author":"Bexte","year":"2024","journal-title":"Mol Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2020","journal-title":"Haematologica"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13094","article-title":"Genetic reprogramming for NK cell cancer immunotherapy with CRISPR\/Cas9","volume":"158","author":"Afolabi","year":"2019","journal-title":"Immunology."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B103","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: From natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226518","article-title":"Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 Complex improved proliferation and anti-tumor effect in vivo. Front","volume":"14","author":"Silvestre","year":"2023","journal-title":"Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR- NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141606","article-title":"Initial clinical activity of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"136","author":"Bachanova","year":"2020","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.14791\/btrt.2022.10.F-1135","article-title":"A phase I first-in-human trial with local application of CAR-NK cells targeting HER2 in patients with recurrent glioblastoma (CAR-2BRAIN): results of the dose-escalation cohort","volume":"10","author":"Burger","year":"2022","journal-title":"Brain Tumor Res Treat"},{"key":"B109","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK- 92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell Malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5167-6","article-title":"Very late relapses in glioblastoma long-term survivors","volume":"256","author":"Bahr","year":"2009","journal-title":"J Neurol"},{"key":"B113","article-title":"Autologous natural killer cell therapy for human recurrent Malignant glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107507118","article-title":"Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e003050","DOI":"10.1136\/jitc-2021-003050","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors","volume":"9","author":"Jan","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00720.x","article-title":"DAP10- and DAP12-associated receptors in innate immunity","volume":"227","author":"Lanier","year":"2009","journal-title":"Immunol Rev"},{"key":"B118","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1 - secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J Immunother."},{"key":"B119","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12951-022-01300-4","article-title":"Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy","volume":"20","author":"Huang","year":"2022","journal-title":"J Nanobiotechnol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000286","article-title":"Anti-aFR CAR- engineered NK-92 cells display potent cytotoxicity against aFR-positive ovarian cancer","volume":"42","author":"Ao","year":"2019","journal-title":"J Immunother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/ijms20030660","article-title":"Characterization of a novel third generation anti-CD24-CAR against ovarian cancer","volume":"20","author":"Klapdor","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101339","article-title":"NK cell- mediated eradication of ovarian cancer cells with a novel chimeric antigen receptor directed against CD44","volume":"9","author":"Klapdor","year":"2021","journal-title":"Biomedicines."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.168","article-title":"Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor-based immunotherapy and chemotherapy","volume":"28","author":"Klapdor","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0809","article-title":"Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis","volume":"104","author":"Menier","year":"2004","journal-title":"Blood."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000286","article-title":"Anti-FR CAR- engineered NK-92 cells display potent cytotoxicity against FR-positive ovarian cancer","volume":"42","author":"Ao","year":"2019","journal-title":"J Immunother."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e12858","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressingoverexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified vectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Schonfeld","year":"2015","journal-title":"Mol Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor- overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","article-title":"Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Sci Rep"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221094244","article-title":"Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell Transpl."},{"key":"B133","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharm"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.576399","article-title":"Stroma-targeting therapy in pancreatic cancer: one coin with two sides","volume":"10","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.29706","article-title":"MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1","volume":"15","author":"He","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13796","article-title":"Robo1-specific CAR-NK immunotherapy enhances efficacy of 125I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma","volume":"39","author":"Xia","year":"2019","journal-title":"Anticancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_190_20","article-title":"Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis","volume":"16","author":"Li","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.07.016","article-title":"Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment","volume":"326","author":"Lee","year":"2020","journal-title":"J Control Release."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2019.05.047","article-title":"Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty\/minicircle vector into NK-92MI cells for treatment of pancreatic cancer","volume":"166","author":"Batchu","year":"2019","journal-title":"Surgery."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.10529","article-title":"Development of c-MET specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells","volume":"20","author":"Liu","year":"2019","journal-title":"Mol Med Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2070562","article-title":"Corrigendum to \u201ccombination therapy with EpCAM-CAR NK-92 cells and regorafenib against human colorectal cancer models","volume":"2019","author":"Zhang","year":"2019","journal-title":"J Immunol Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2022.09.021","article-title":"Comprehensive analysis of tumor necrosis factor-alpha-inducible protein 8-like 2 (TIPE2): a potential novel pan-cancer immune checkpoint","volume":"20","author":"Bai","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6915912","article-title":"Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma","volume":"2017","author":"Zhang","year":"2017","journal-title":"J Immunol Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol Ther Oncolytics."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1002720","article-title":"Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies\u2013A review","volume":"4","author":"Nayar","year":"2015","journal-title":"Oncoimmunology."},{"key":"B151","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discovery"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167666","article-title":"The application of autologous cancer immunotherapies in the age of memory-NK cells","volume":"14","author":"Lizana-Vasquez","year":"2023","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope specific car exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B157","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","article-title":"Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010164","article-title":"Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors","volume":"23","author":"Lian","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166038","article-title":"Advancements in CAR- NK therapy: lessons to be learned from CAR-T therapy","volume":"14","author":"Kilgour","year":"2023","journal-title":"Front Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638841","article-title":"Interaction between MDSC and NK cells in solid and hematological Malignancies: impact on HSCT","volume":"12","author":"Tumino","year":"2021","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.057","article-title":"Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner","author":"Hosseinalizadeh","year":"2025","journal-title":"Mol Ther"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1238","article-title":"Arrested development: suppression of NK cell function in the tumor microenvironment","volume":"10","author":"Riggan","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new car-based therapies with a focus on CAR NK cells: what lies beyond car-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discovery."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.327","article-title":"The TGF-\u03b2\/smad pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia","volume":"30","author":"Rouce","year":"2016","journal-title":"Leukemia."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191358","article-title":"Inhibiting tgf-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models","volume":"13","author":"Otegbeye","year":"2018","journal-title":"PloS One"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nat Rev Cancer."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101225","article-title":"Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells","volume":"187","author":"Ryzhov","year":"2011","journal-title":"J Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.007","article-title":"CD39\/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice","volume":"139","author":"Sun","year":"2010","journal-title":"Gastroenterology."},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J Immunother Cancer."},{"key":"B171","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses","volume":"30","author":"Young","year":"2016","journal-title":"Cancer Cell"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Res"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302091","article-title":"CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-\u03b3 production in response to mature dendritic cells","volume":"192","author":"Stojanovic","year":"2014","journal-title":"J Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001110","article-title":"Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation","volume":"5","author":"Davis","year":"2021","journal-title":"Blood Adv"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0386","article-title":"Anti\u2013CTLA-4 activates intratumoral NK cells and combined with IL15\/IL15R\u03b1 complexes enhances tumor control","volume":"7","author":"Sanseviero","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Investig"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint\u2014a new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer."},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti- NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell."},{"key":"B183","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for car-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1738378","article-title":"Prospects and challenges for use of car T cell therapies in solid tumors","volume":"20","author":"Ramakrishna","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific car-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell Malignancies with off-the-shelf dual-car NK- 92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J Trans Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017794","article-title":"Engineering builds multipotency for IPSC-NKs","volume":"140","author":"Rahnama","year":"2022","journal-title":"Blood."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in car T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of car-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharmacol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Supplement to: inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Stasi","year":"2011","journal-title":"New Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-019-0714-8","article-title":"Management of cytokine release syndrome related to CAR-T cell therapy","volume":"13","author":"Chen","year":"2019","journal-title":"J Energy Chem"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013 induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell Malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06193-1","article-title":"Acute life-threatening toxicity from CAR T-cell therapy","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood."},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859177","article-title":"Innovative strategies to improve the clinical application of NK cell-based immunotherapy","volume":"13","author":"Tarannum","year":"2022","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1135468","article-title":"Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy","volume":"10","author":"Chen","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27196","article-title":"CAR-NK cells in combination therapy against cancer: A potential paradigm","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1574742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T01:24:28Z","timestamp":1743989068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1574742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":198,"alternative-id":["10.3389\/fimmu.2025.1574742"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1574742","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1574742.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1574742"}}